The domestic equity markets opened lower, with Nifty 50 down 0.32% and BSE Sensex down 0.33%. Analysts suggest that despite ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Australia on Friday blocked a A$672 million ($433 million) buyout offer for Mayne Pharma from U.S. drugmaker Cosette Pharmaceuticals, citing national interest.

4. Salesforce, Inc. (CRM) - Raymond James has established a $375 price target for Salesforce, currently trading at $237.03.

Tarsus Pharmaceuticals, Inc. upgraded to Strong Buy; Xdemvy's rapid US growth and unique market lead highlight big upside.

For the past two decades, large multinational pharmaceutical companies have increasingly withdrawn from researching medicines ...

Despite STERIS' outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

F or Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably ...

Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...

Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle cell ...

In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula ...